Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)
Follicular Lymphoma|Relapsed and Refractory Follicular Lymphoma
DRUG: Orelabrutinib and Rituximab|DRUG: Orelabrutinib
Objective Response rate, Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria., 2 years
Complete remission rate, Complete remission rate will be determined on the basis of investigator, 2 years|Progression Free Survival, The time from the start of treatment to the progression of the tumor or death (due to any cause)., 4 years|Overall Survival, The time from the start of treatment to time of death (due to any cause)., 4 years|Duration of Response, The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause)., 4 years|Percentage of Participants With Adverse Events, Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0, 4 years
This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)